» Articles » PMID: 33691727

The Association of Secondary Hyperparathyroidism and Myocardial Damages in Hemodialysis End-stage Renal Disease Patients: Assessed by Cardiovascular Magnetic Resonance Native T1 Mapping

Overview
Publisher Elsevier
Date 2021 Mar 11
PMID 33691727
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Secondary hyperparathyroidism is a common complication of end-stage renal disease (ESRD), which may be associated with cardiovascular diseases. Thus, this study aimed to explore myocardial damage using non-contrast cardiovascular magnetic resonance (CMR) in ESRD patients undergoing hemodialysis and further investigate its relationship with parathyroid hormone (PTH) toxicity.

Methods: Seventy-two adult ESRD patients receiving regular hemodialysis and 30 healthy subjects underwent CMR examination. Continuous CMR cine sections from the mitral valve level to the left ventricular (LV) apex in the short-axis plane, cine series of vertical two-chamber long-axis plane, and horizontal four-chamber plane were acquired. Native T1 mapping was obtained using modified Look-Locker inversion recovery (MOLLI) sequences. Native T1 values and myocardial strain were analyzed.  Immunoreactive parathyroid hormone (iPTH) was obtained from all enrolled patients.

Results: Forty (55.6%) hemodialysis ESRD patients were found to have increased iPTH levels. LV ejection fraction (LVEF) of both ESRD patients with targeted and increased iPTH levels was decreased compared with healthy subjects (55.9 ± 12.0% vs. 65.0 ± 4.5%; 51.7 ± 12.8 vs. 65.0 ± 4.5%, both P < 0.05). The mean peak radial strain (PRS), peak circumferential strain (PCS), and peak longitudinal strain (PLS) were lowest in ESRD patients with increased iPTH; however, no significant difference was observed among these three groups. Segmentally, from base to apex, the native T1 of ESRD patients with increased iPTH levels tended to be higher than those with targeted iPTH and healthy subjects (all P < 0.05). In ESRD patients with targeted iPTH, both native T1 of basal and middle segments were significantly higher than normal subjects (basal, 1304 ± 41 ms vs. 1238 ± 36 ms, P = 0.001; middle, 1300 ± 43 ms vs. 1242 ± 50 ms, P < 0.001). Comparing global native T1 values in the three groups, ESRD patients with targeted and increased iPTH level showed increased native T1 (1305 ± 41 ms vs. 1251 ± 49 ms, P = 0.001; 1334 ± 40 ms vs. 1251 ± 49 ms, P < 0.001, respectively). Native T1 values of the basal segment and global native T1 were moderately associated with iPTH (r = 0.4, P < 0.001; r = 0.5, P < 0.001). Multiple linear regression analysis showed that global native T1 values (beta = 1.0, P = 0.01) were independently associated with iPTH.

Conclusions: Elevated iPTH level was associated with and was an independent risk factor for myocardial damage in ESRD patients undergoing maintenance hemodialysis.

Trial Registration: Chinese Clinical Trial Registry ( http://www.chictr.org.cn/index.aspx ) ChiCTR-DND-17012976, 13/12/2017, retrospectively registered.

Citing Articles

Impact of successful secondary hyperparathyroidism treatment on cardiovascular morbidity in patients with chronic kidney disease KDIGO stages G3b-5.

Da Canal F, Breuer E, Hubel K, Mikulicic F, Buechel R, de Rougemont O Ir J Med Sci. 2024; 193(6):2723-2732.

PMID: 39215777 DOI: 10.1007/s11845-024-03770-x.


Causal factors of cardiovascular disease in end-stage renal disease with maintenance hemodialysis: a longitudinal and Mendelian randomization study.

Tian D, Xu Y, Wang Y, Zhu X, Huang C, Liu M Front Cardiovasc Med. 2024; 11:1306159.

PMID: 39091361 PMC: 11291196. DOI: 10.3389/fcvm.2024.1306159.


Coronary Artery Disease in Patients Undergoing Hemodialysis: A Problem that Sounds the Alarm.

Barbuto S, Hu L, Abenavoli C, Picotti M, La Manna G, De Nicola L Rev Cardiovasc Med. 2024; 25(6):200.

PMID: 39076335 PMC: 11270123. DOI: 10.31083/j.rcm2506200.


Treatment for secondary hyperparathyroidism focusing on parathyroidectomy.

Hiramitsu T, Hasegawa Y, Futamura K, Okada M, Goto N, Narumi S Front Endocrinol (Lausanne). 2023; 14:1169793.

PMID: 37152972 PMC: 10159274. DOI: 10.3389/fendo.2023.1169793.


Association of Anemia with Parathyroid Hormone Levels and Other Factors in Patients with End-Stage Renal Disease Undergoing Hemodialysis: A Cross-Sectional, Real-World Data Study in Pakistan.

Bukhari H, Ahmad A, Noorin A, Khan A, Mushtaq M, Naeem A Int J Clin Pract. 2023; 2023:7418857.

PMID: 36815007 PMC: 9940945. DOI: 10.1155/2023/7418857.

References
1.
Miller E, Schwartz R . Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe, effective, and well tolerated: Does it matter?. J Nucl Cardiol. 2015; 24(1):119-121. DOI: 10.1007/s12350-015-0337-7. View

2.
Gansevoort R, Correa-Rotter R, Hemmelgarn B, Jafar T, Lambers Heerspink H, Mann J . Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382(9889):339-52. DOI: 10.1016/S0140-6736(13)60595-4. View

3.
Fatema K, Hirono O, Takeishi Y, Nitobe J, Kaneko K, Ito M . Hemodialysis improves myocardial interstitial edema and left ventricular diastolic function in patients with end-stage renal disease: noninvasive assessment by ultrasonic tissue characterization. Heart Vessels. 2002; 16(6):227-31. DOI: 10.1007/s003800200029. View

4.
Cottone S, Lorito M, Riccobene R, Nardi E, Mule G, Buscemi S . Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J Nephrol. 2008; 21(2):175-9. View

5.
Amann K, Ritz E, Wiest G, Klaus G, Mall G . A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol. 1994; 4(10):1814-9. DOI: 10.1681/ASN.V4101814. View